Advanced Filters
noise

Shenzhen, China Clinical Trials

A listing of Shenzhen, China clinical trials actively recruiting patients volunteers.

Found 204 clinical trials
V Vitaly Dubov, MD

Engineered Dendritic Cell Vaccines for Multiple Myeloma

The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.

18 - 80 years of age All Phase 1
x xiaoyang hong

Prone Position During ECMO in Pediatric Patients With Severe ARDS

In 2023, the second Pediatric Acute Lung Injury Consensus Conference (PALICC-2) updated the diagnostic and management guidelines for Pediatric Acute Respiratory Distress Syndrome (PARDS). The guidelines do not provide sufficient evidence-based recommendations on whether prone positioning ventilation is necessary for severe PARDS patients. However, the effectiveness of Extracorporeal Membrane Oxygenation …

1 - 18 years of age All Phase N/A
H Haibo Chen

Corheart 6: Long-term Cohort Study

This study aims to evaluate the long-term effectiveness and safety of Corheart 6 left ventricular assist system as a treatment for patients with advanced left heart failure. The patients who have received the Corheart 6 treatment since October 2021, or who are planned to received it, will be enrolled until …

18 years of age All Phase N/A
Q Qingqing Cai, MD

Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)

This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of orelabrutinib combined with the R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) regimen as first-line treatment in CD5-positive diffuse large B-cell lymphoma (DLBCL) patients.

18 years of age All Phase 2

A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.

To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy

18 - 80 years of age All Phase 2/3
T Tao Luo, MD,PHD

Effect of MGRNOX Index-Guided General Anesthesia on Opioid Consumption in Patients

Pain management is a crucial part of general anesthesia surgery. Nociception monitoring can help anesthesiologists better titrate the use of intraoperative analgesic drugs, especially the opioid. Although a variety of nociception monitoring devices have been developed to date, there is not a specific monitoring indicator that serves as the "gold …

18 - 64 years of age All Phase N/A
L Lung-Ji Chang, Ph.D

Combination Immunotherapy Targeting Melanoma

The purpose of this study is to assess the feasibility, safety and efficacy of combination immunotherapy based on CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines modified with GM-CSF and B7-2 (CD86) against melanoma, which targets CAR T specific surface antigens such as GD2, CTL specific …

18 - 75 years of age All Phase 1/2
T Tao Luo, MD,PHD

Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality

Eligible patients are randomly divided into experimental and control groups; The experimental group is given esketamine combined with dexmedetomidine,while the control group is given normal saline; The patients' sleep, pain, and cognition are followed up after surgery.

65 years of age All Phase N/A
L Lung-Ji Chang, Ph.D

IT and IV Lentiviral Gene Therapy for X-ALD

This is a Phase I/II clinical trial of gene therapy for treating X-linked adrenoleukodystrophy using a high-safety, high-efficiency, self-inactivating lentiviral vector (LV) TYF-ABCD1 to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the intrathecal and intravenous lentiviral gene transfer clinical protocol.

1 - 60 years of age All Phase N/A
L Lung-Ji Chang, Ph.D

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Patients with refractory and/or recurrent solid tumor have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. The investigators are attempt to treat these diseases using T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (4SCAR fused with an inducible apoptotic caspase 9 …

1 - 65 years of age All Phase 1/2

Simplify language using AI